SABCS 2022 Conference Coverage


 

SABCS 2022 Dose-Expansion Study DESTINY-Breast07: T-DXd as Monotherapy or Combined With Pertuzumab in Patients With Metastatic HER2+ BC

177 views
December 22, 2022
Comments 0
Login to view comments. Click here to Login